PKA inhibitor fragment (6-22) amide
Cat. No. 1904
Alternative Names: Protein kinase inhibitor-(6-22)-amide, PKI-(6-22)-amide
Biological ActivityPotent inhibitor of cAMP-dependent protein kinase (PKA) (Ki = 2.5 nM); derived from the active portion of the heat-stable PKA inhibitor protein PKI.
(Modifications: Ile-17 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Glass et al (1989) Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. J.Biol.Chem. 264 8802. PMID: 2722799.
Glass et al (1989) Protein kinase inhibitor-(6-22)-amide peptide analogs with standard and nonstandard amino acid substitutions for phenylalanine 10. J.Biol.Chem. 264 14579. PMID: 2760075.
Otmakhova et al (2000) Inhibition of the cAMP pathway decreases early long-term potentiation at CA1 hippocampal synapses. J.Neurosci. 20 4446. PMID: 10844013.
If you know of a relevant citation for this product please let us know.
Keywords: PKA Inhibitor Fragment (6-22) amide, supplier, Potent, protein, kinases, A, inhibitors, PKA
Find multiple products by catalog number
New Products in this Area
Glucokinase activatorMRT 67307 dihydrochloride
Salt inducible kinase (SIK) inhibitorLDN 209929 dihydrochloride
Potent and selective haspin kinase inhibitorRKI 1447 dihydrochloride
Potent and selective ROCK inhibitor; antitumorLIMKi 3
Potent LIM kinase inhibitor; antitumorFRAX 486
Potent p21-activated kinase (PAK) inhibitor; brain penetrant and orally bioavailableBIX 02189
Selective MEK5 and ERK5 inhibitorTC Mps1 12
Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor; orally activeGSK 2606414
Potent and selective PERK inhibitor; orally bioavailableAZ 20
Potent and selective ATR kinase inhibitor; antitumorAZD 7762 hydrochloride
Potent and selective ATP-competitive inhibitor of Chk1 and Chk2PHT 427
Dual Akt and PDK1 inhibitor; antitumorML 786 dihydrochloride
Potent Raf kinase inhibitor; orally bioavailableSenexin A
Cyclin-dependent kinase 8 (cdk8) inhibitorXL 388
Potent and selective mTOR inhibitor; antitumorPS 1145 dihydrochloride
Selective IKK inhibitor; orally active
November 15 - 19, 2014
Washington D.C., USA